CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 14,429	$ 7,428	$ 39,952	$ 19,759
Research and development - related party		1,000		1,000
General and administrative	3,751	3,342	10,868	9,027
Total operating expenses	18,180	11,770	50,820	29,786
Loss from operations	(18,180)	(11,770)	(50,820)	(29,786)
Other income, net	1,473	431	2,986	672
Net loss	(16,707)	(11,339)	(47,834)	(29,114)
Accretion to redemption value and cumulative dividends on preferred stock				(1,820)
Net loss attributable to common stockholders	$ (16,707)	$ (11,339)	$ (47,834)	$ (30,934)
Net loss per share attributable to common stockholders, basic	$ (0.65)	$ (0.59)	$ (2.22)	$ (2.21)
Net loss per share attributable to common stockholders, diluted	$ (0.65)	$ (0.59)	$ (2.22)	$ (2.21)
Weighted-average number of shares used in computing net loss per share, basic	25,645,421	19,347,148	21,532,537	13,987,862
Weighted-average number of shares used in computing net loss per share, diluted	25,645,421	19,347,148	21,532,537	13,987,862
Other comprehensive loss:
Unrealized gain (loss) on investments	$ (3)	$ (181)	$ 252	$ (514)
Comprehensive loss	$ (16,710)	$ (11,520)	$ (47,582)	$ (29,628)